rituximab + chemotherapy + tenofovir alafenamide

This therapeutic regimen is a combination treatment being evaluated by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) in the GIMEMA CLL1818 clinical trial. The regimen consists of the antiviral **tenofovir alafenamide (TAF)**, the anti-CD20 monoclonal antibody **rituximab**, and standard **chemotherapy**. It is specifically designed to prevent hepatitis B virus (HBV) reactivation in HBsAg-positive patients who are undergoing treatment for B-cell malignancies, such as diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL). Tenofovir alafenamide, developed by Gilead Sciences, is a nucleotide reverse transcriptase inhibitor that targets the HBV polymerase enzyme to suppress viral replication. Rituximab targets CD20-positive B-cells to treat the underlying cancer. In this protocol, TAF is initiated before cancer treatment and continued as monotherapy for 12 months following the completion of chemotherapy to ensure sustained viral suppression during the period of profound immunosuppression.

Brand names

VemlidyRituxanMabThera

Other names

chemotherapy-Gruppo Italiano Malattie EMatologiche dell'Adulto-hepatitis BRituximab + Chemotherapy + TAFTAF + R-Chemo